Thomas Woiwode's most recent trade in Passage Bio Inc was a trade of 24,000 Director Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 25, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Passage Bio Inc | Thomas F. Woiwode | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 24,000 | 24,000 | - | - | Director Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Tempest Therapeutics Inc | Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 3,500 | 3,500 | - | - | Stock Option (Right to Buy) | |
| Passage Bio Inc | Thomas Woiwode | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 24,000 | 24,000 | - | - | Director Stock Option (Right to Buy) | |
| Tempest Therapeutics Inc | Thomas Woiwode | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.36 per share. | 29 Apr 2022 | 2,118,644 | 2,118,644 | - | 2.4 | 5,000,000 | Common Stock |
| Gritstone Bio Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 25 Aug 2021 | 444,744 | 902,965 (2%) | 1% | 0 | Common Stock | |
| Gritstone Bio Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 25 Aug 2021 | 6,668 | 0 (0%) | 0% | 0 | Common Stock | |
| Gritstone Bio Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 25 Aug 2021 | 6,668 | 6,668 (0%) | 0% | 0 | Common Stock | |
| Gritstone Bio Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 25 Aug 2021 | 6,612 | 0 (0%) | 0% | 0 | Common Stock | |
| Gritstone Bio Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 25 Aug 2021 | 6,612 | 6,612 (0%) | 0% | 0 | Common Stock | |
| Gritstone Bio Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 25 Aug 2021 | 128 | 128 (0%) | 0% | 0 | Common Stock | |
| Tempest Therapeutics Inc | Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 6,635 | 6,635 | - | - | Stock Option (Right to Buy) | |
| Tempest Therapeutics Inc | Thomas Woiwode | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 1,171,094 | 1,171,094 | - | - | Common Stock | |
| Tempest Therapeutics Inc | Thomas Woiwode | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 997,940 | 997,940 | - | - | Common Stock | |
| Tempest Therapeutics Inc | Thomas Woiwode | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 7,377 | 7,377 | - | - | Common Stock | |
| Aligos Therapeutics Inc | Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Passage Bio Inc | Thomas Woiwode | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 16,918 | 16,918 | - | - | Director Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 485,979 | 1,943,916 | - | 0 | Common Stock | |
| Aligos Therapeutics Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 9,720 | 9,720 | - | 0 | Common Stock | |
| Aligos Therapeutics Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 9,720 | 0 | - | 0 | Common Stock | |
| Aligos Therapeutics Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 8,385 | 8,385 | - | 0 | Common Stock | |
| Aligos Therapeutics Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 8,385 | 0 | - | 0 | Common Stock | |
| Aligos Therapeutics Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 2,226 | 2,226 | - | 0 | Common Stock | |
| Adverum Biotechnologies Inc | Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 14 Dec 2020 | 12,783 | 18,822 (0%) | 0% | 0 | Common Stock | |
| Aligos Therapeutics Inc | Thomas Woiwode | Director | 20 Oct 2020 | 2,145,991 | 2,145,991 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Thomas Woiwode | Director | 20 Oct 2020 | 2,145,991 | 0 | - | - | Series A Preferred Stock | ||
| Aligos Therapeutics Inc | Thomas Woiwode | Director | 20 Oct 2020 | 463,959 | 463,959 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Thomas Woiwode | Director | 20 Oct 2020 | 463,959 | 0 | - | - | Series B-1 Preferred Stock | ||
| Aligos Therapeutics Inc | Thomas Woiwode | Director | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 20 Oct 2020 | 200,000 | 862,444 | - | 15 | 3,000,000 | Common Stock |
| Aligos Therapeutics Inc | Thomas Woiwode | Director | 20 Oct 2020 | 198,839 | 2,344,830 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Thomas Woiwode | Director | 20 Oct 2020 | 198,839 | 0 | - | - | Series B-1 Preferred Stock | ||
| Aligos Therapeutics Inc | Thomas Woiwode | Director | 20 Oct 2020 | 198,485 | 662,444 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Thomas Woiwode | Director | 20 Oct 2020 | 198,485 | 0 | - | - | Series B-2 Preferred Stock | ||
| Aligos Therapeutics Inc | Thomas Woiwode | Director | 20 Oct 2020 | 85,065 | 2,429,895 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Thomas Woiwode | Director | 20 Oct 2020 | 85,065 | 0 | - | - | Series B-2 Preferred Stock |